Article
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
American journal of respiratory and critical care medicine - 15 Mar 2003
Gibson Ronald L, Emerson Julia, McNamara Sharon, Burns Jane L, Rosenfeld Margaret, Yunker Ann, Hamblett Nicole, Accurso Frank, Dovey Mark, Hiatt Peter, Konstan Michael W, Moss Richard, Retsch-Bogart George, Wagener Jeffrey, Waltz David, Wilmott Robert, Zeitlin Pamela L, Ramsey Bonnie
Abstract excerpt
We conducted a double-blind, placebo-controlled, multicenter, randomized trial to test the hypothesis that 300 mg of tobramycin solution for inhalation administered twice daily for 28 days would be safe and result in a profound decrease in Pseudomonas aeruginosa (Pa) density from the lower airway of young children with cystic fibrosis. Ninety-eight subjects were to be randomized; however, the trial was stopped...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.